Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC.

ABSTRACT:

Introduction

Hyperprogressive disease (HPD) as a consequence of immune checkpoint inhibitors in NSCLC has been reported in multiple studies. However, inconsistent results in incidence and survival outcomes within studies, together with different assessment methods, have led to increasing controversy regarding the concept of HPD.

Methods

Consecutive patients treated with nivolumab (N = 42) or docetaxel (N = 37) were evaluated. HPD was quantified by applying three different methods (tumor growth rate [TGR], tumor growth kinetics [TGK], and Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1]). HPD rates were compared between and within both cohorts using the different methods.

Results

Using TGR, TGK, and RECIST 1.1, we identified seven (16.7%), seven (1

SUBMITTER: Rocha P 

PROVIDER: S-EPMC8474364 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature